Description
The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab300 mg administered subcutaneously (SC) every 2 weeks (Q2W) in adult participants with symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a history of = 2 moderate or = 1 severe exacerbations of COPD in the 12 months prior to enrolment.
